Quarterly
Annual
| Unit: USD | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-06-30 | 2014-03-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | |||||||||||||||||||||||||||||||||||||||||||||
testing revenue | 127,756,000 | 122,263,000 | 107,309,000 | 112,152,000 | 109,536,000 | 106,970,000 | 90,303,000 | 90,385,000 | 82,012,000 | 81,749,000 | 72,396,000 | 70,269,000 | 64,577,000 | 59,718,000 | 55,980,000 | 53,414,000 | 50,897,000 | 50,793,000 | 33,078,000 | 31,497,000 | 28,270,000 | 15,212,000 | 26,991,000 | ||||||||||||||||||||||
product revenue | 3,301,000 | 3,598,000 | 3,580,000 | 3,019,000 | 3,188,000 | 3,906,000 | 3,537,000 | 3,665,000 | 4,020,000 | 4,011,000 | 3,892,000 | 3,231,000 | 3,314,000 | 3,108,000 | 2,979,000 | 2,758,000 | 2,959,000 | 2,688,000 | 3,059,000 | 2,696,000 | 2,027,000 | 1,713,000 | 3,409,000 | ||||||||||||||||||||||
biopharmaceutical and other revenue | 815,000 | 4,303,000 | 3,584,000 | 3,461,000 | 3,136,000 | 3,552,000 | 3,004,000 | 4,149,000 | 4,076,000 | 4,562,000 | 6,134,000 | 6,797,000 | 7,701,000 | 10,038,000 | 8,824,000 | 11,164,000 | 6,514,000 | ||||||||||||||||||||||||||||
total revenue | 131,872,000 | 130,164,000 | 114,473,000 | 118,632,000 | 115,860,000 | 114,428,000 | 96,844,000 | 98,199,000 | 90,108,000 | 90,322,000 | 82,422,000 | 80,297,000 | 75,592,000 | 72,864,000 | 67,783,000 | 67,336,000 | 60,370,000 | 55,105,000 | 36,703,000 | 34,536,000 | 31,121,000 | 20,704,000 | 31,122,000 | ||||||||||||||||||||||
yoy | 13.82% | 13.75% | 18.20% | 20.81% | 28.58% | 26.69% | 17.50% | 22.29% | 19.20% | 23.96% | 21.60% | 19.25% | 25.21% | 32.23% | 84.68% | 94.97% | 93.98% | 166.16% | 17.93% | ||||||||||||||||||||||||||
qoq | 1.31% | 13.71% | -3.51% | 2.39% | 1.25% | 18.16% | -1.38% | 8.98% | -0.24% | 9.58% | 2.65% | 6.22% | 3.74% | 7.50% | 0.66% | 11.54% | 9.55% | 50.14% | 6.27% | 10.97% | 50.31% | -33.47% | |||||||||||||||||||||||
cost of revenue: | |||||||||||||||||||||||||||||||||||||||||||||
cost of testing revenue | 33,777,000 | 32,407,000 | 28,260,000 | 31,645,000 | 29,029,000 | 27,920,000 | 25,979,000 | 24,105,000 | 21,827,000 | 23,333,000 | 19,648,000 | 19,394,000 | 19,816,000 | 18,584,000 | 17,523,000 | 16,366,000 | 16,073,000 | 15,589,000 | 10,832,000 | 9,756,000 | 9,118,000 | 6,471,000 | 10,568,000 | ||||||||||||||||||||||
cost of product revenue | 3,015,000 | 1,749,000 | 1,422,000 | 2,800,000 | 1,792,000 | 1,874,000 | 2,644,000 | 1,753,000 | 2,436,000 | 2,315,000 | 2,162,000 | 2,618,000 | 1,981,000 | 1,646,000 | 1,575,000 | 1,583,000 | 1,491,000 | 1,323,000 | 1,490,000 | 1,382,000 | 1,048,000 | 932,000 | 1,559,000 | ||||||||||||||||||||||
cost of biopharmaceutical and other revenue | 1,091,000 | 3,572,000 | 2,698,000 | 2,622,000 | 3,112,000 | 3,812,000 | 2,838,000 | 3,518,000 | 3,347,000 | 4,040,000 | 4,419,000 | 4,819,000 | 4,211,000 | 4,800,000 | 4,615,000 | 4,933,000 | 4,079,000 | ||||||||||||||||||||||||||||
intangible asset amortization - cost of revenue | 2,707,000 | 2,667,000 | 2,585,000 | 2,811,000 | 2,917,000 | 2,909,000 | |||||||||||||||||||||||||||||||||||||||
total cost of revenue | 40,590,000 | 40,395,000 | 34,965,000 | 39,878,000 | 36,850,000 | 36,515,000 | |||||||||||||||||||||||||||||||||||||||
gross profit | 91,282,000 | 89,769,000 | 79,508,000 | 78,754,000 | 79,010,000 | 77,913,000 | |||||||||||||||||||||||||||||||||||||||
yoy | 15.53% | 15.22% | |||||||||||||||||||||||||||||||||||||||||||
qoq | 1.69% | 12.91% | 0.96% | -0.32% | 1.41% | ||||||||||||||||||||||||||||||||||||||||
gross margin % | 69.22% | 68.97% | 69.46% | 66.39% | 68.19% | 68.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||||||||||
operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||
research and development | 15,981,000 | 16,264,000 | 17,720,000 | 19,290,000 | 17,574,000 | 16,465,000 | 15,965,000 | 18,673,000 | 13,322,000 | 12,541,000 | 12,769,000 | 11,287,000 | 10,773,000 | 9,377,000 | 9,166,000 | 10,252,000 | 8,006,000 | 6,249,000 | 5,336,000 | 4,586,000 | 4,042,000 | 4,169,000 | 4,407,000 | 4,443,000 | 3,643,000 | 3,330,000 | 3,435,000 | 3,125,000 | 3,419,000 | 4,601,000 | 3,675,000 | 3,202,000 | 3,046,000 | 3,603,000 | 4,030,000 | 3,590,000 | 4,006,000 | 4,267,000 | 3,461,000 | 3,563,000 | 3,103,000 | 2,787,000 | 2,243,000 | 2,126,000 | 2,028,000 |
selling and marketing | 24,455,000 | 25,316,000 | 24,454,000 | 24,824,000 | 22,612,000 | 24,216,000 | 23,782,000 | 25,260,000 | 24,344,000 | 25,756,000 | 26,130,000 | 24,127,000 | 25,678,000 | 24,001,000 | 23,754,000 | 22,212,000 | 21,670,000 | 19,662,000 | 16,296,000 | 13,149,000 | 10,955,000 | 10,701,000 | 17,584,000 | 14,183,000 | 13,088,000 | 13,943,000 | 12,477,000 | 10,066,000 | 10,081,000 | 9,623,000 | 11,543,000 | 9,045,000 | 7,885,000 | 7,994,000 | 7,336,000 | 5,832,000 | 7,087,000 | 8,263,000 | 7,066,000 | 6,048,000 | 6,937,000 | 5,620,000 | 5,101,000 | 4,336,000 | 3,291,000 |
general and administrative | 27,278,000 | 32,331,000 | 33,808,000 | 26,913,000 | 25,742,000 | 31,745,000 | 26,210,000 | 23,795,000 | 16,334,000 | 25,047,000 | 22,463,000 | 18,208,000 | 17,600,000 | 19,798,000 | 20,912,000 | 18,849,000 | 20,749,000 | 15,473,000 | 46,282,000 | 12,413,000 | 8,546,000 | 7,957,000 | 7,813,000 | 8,581,000 | 6,624,000 | 6,920,000 | 6,904,000 | 6,645,000 | 5,742,000 | 5,932,000 | 5,644,000 | 5,357,000 | 5,520,000 | 6,192,000 | 6,019,000 | 5,725,000 | 5,763,000 | 6,071,000 | 6,228,000 | 5,728,000 | 5,536,000 | 5,798,000 | 3,928,000 | 3,982,000 | 3,244,000 |
impairment of assets | 20,505,000 | ||||||||||||||||||||||||||||||||||||||||||||
intangible asset amortization - operating expenses | 622,000 | 621,000 | 622,000 | 798,000 | 880,000 | 881,000 | |||||||||||||||||||||||||||||||||||||||
total operating expenses | 68,336,000 | 95,037,000 | 76,604,000 | 74,579,000 | 66,993,000 | 73,307,000 | 101,500,000 | 133,706,000 | 121,847,000 | 98,373,000 | 92,920,000 | 85,717,000 | 85,272,000 | 83,597,000 | 83,031,000 | 79,669,000 | 77,051,000 | 62,579,000 | 82,118,000 | 42,608,000 | 35,187,000 | 31,755,000 | 43,322,000 | 37,927,000 | 32,736,000 | 33,236,000 | 31,596,000 | 28,807,000 | 27,770,000 | 28,668,000 | 28,996,000 | 25,640,000 | 23,887,000 | 25,015,000 | 23,949,000 | 21,929,000 | 23,489,000 | 25,169,000 | 23,301,000 | 21,223,000 | 20,982,000 | 18,771,000 | 15,238,000 | 14,051,000 | 11,695,000 |
income from operations | 22,946,000 | -5,268,000 | 2,904,000 | 4,175,000 | 12,017,000 | 4,606,000 | -4,656,000 | -35,507,000 | -31,739,000 | -8,051,000 | -10,498,000 | -5,420,000 | -9,680,000 | -10,733,000 | -15,248,000 | -12,333,000 | -16,681,000 | -7,474,000 | -45,415,000 | -8,072,000 | -4,066,000 | -11,051,000 | -12,200,000 | -8,197,000 | -1,763,000 | -3,100,000 | -2,067,000 | -3,057,000 | -4,304,000 | -5,917,000 | -8,955,000 | -6,044,000 | -6,368,000 | -6,609,000 | -7,517,000 | -3,672,000 | -4,886,000 | -10,494,000 | |||||||
yoy | 90.95% | -214.37% | -162.37% | -111.76% | -137.86% | -157.21% | -55.65% | 555.11% | 227.88% | -24.99% | -31.15% | -56.05% | -41.97% | 43.60% | -66.43% | 52.79% | 310.26% | -32.37% | 272.25% | -1.52% | 130.63% | 256.48% | 490.23% | 168.14% | -59.04% | -47.61% | -76.92% | -49.42% | -32.41% | -10.47% | 19.13% | 64.60% | 30.33% | -37.02% | |||||||||||
qoq | -535.57% | -281.40% | -30.44% | -65.26% | 160.90% | -198.93% | -86.89% | 11.87% | 294.22% | -23.31% | 93.69% | -44.01% | -9.81% | -29.61% | 23.64% | -26.07% | 123.19% | -83.54% | 462.62% | 98.52% | -63.21% | -9.42% | 48.83% | 364.95% | -43.13% | 49.98% | -32.38% | -28.97% | -27.26% | -33.93% | 48.16% | -5.09% | -3.65% | -12.08% | 104.71% | -24.85% | -53.44% | ||||||||
operating margin % | 17.40% | -4.05% | 2.54% | 3.52% | 10.37% | 4.03% | -4.81% | -36.16% | -35.22% | -8.91% | -12.74% | -6.75% | -12.81% | -14.73% | -22.50% | -18.32% | -27.63% | -13.56% | -123.74% | -23.37% | -13.07% | -53.38% | -39.20% | ||||||||||||||||||||||
other income | -4,057,000 | 6,518,000 | 4,524,000 | -732,000 | 4,831,000 | 2,755,000 | 2,748,000 | 5,035,000 | 1,967,000 | -226,000 | 2,407,000 | 1,979,000 | 805,000 | 1,086,000 | 784,000 | 1,016,000 | 1,202,000 | -1,653,000 | -195,000 | 82,000 | -3,000 | 91,000 | 539,000 | 820,000 | 1,091,000 | 841,000 | 453,000 | 488,000 | 333,000 | 150,000 | 226,000 | 123,000 | 134,000 | 119,000 | 100,000 | 75,000 | 48,000 | 36,000 | 43,000 | 35,000 | 28,000 | 32,000 | 19,000 | 12,000 | |
income before income taxes | 18,889,000 | 1,250,000 | 7,428,000 | 3,443,000 | 16,848,000 | 7,361,000 | -1,908,000 | -11,535,000 | -29,772,000 | -8,277,000 | -8,091,000 | -8,246,500 | -8,875,000 | -9,647,000 | -14,464,000 | ||||||||||||||||||||||||||||||
income tax benefit | -248,000 | 381,000 | -1,670,000 | 1,693,000 | -44,000 | -2,179,000 | -154,000 | 125,000 | 403,000 | -152,000 | -115,000 | -3,000 | -789,000 | -1,350,000 | -152,000 | -3,795,000 | |||||||||||||||||||||||||||||
net income | 19,137,000 | -980,000 | 7,047,000 | 5,113,000 | 15,155,000 | 5,734,000 | -1,864,000 | -28,293,000 | -29,618,000 | -8,402,000 | -8,091,000 | -3,844,000 | -8,723,000 | -9,532,000 | -14,461,000 | -10,528,000 | -14,129,000 | ||||||||||||||||||||||||||||
yoy | 26.28% | -117.09% | -478.06% | -118.07% | -151.17% | -168.25% | -76.96% | 636.03% | 239.54% | -11.85% | -44.05% | -63.49% | -38.26% | ||||||||||||||||||||||||||||||||
qoq | -2052.76% | -113.91% | 37.83% | -66.26% | 164.30% | -407.62% | -93.41% | -4.47% | 252.51% | 3.84% | 110.48% | -55.93% | -8.49% | -34.08% | 37.36% | -25.49% | |||||||||||||||||||||||||||||
net income margin % | 14.51% | -0.75% | 6.16% | 4.31% | 13.08% | 5.01% | -1.92% | -28.81% | -32.87% | -9.30% | -9.82% | -4.79% | -11.54% | -13.08% | -21.33% | -15.64% | -23.40% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||||||||||||
earnings per share: | |||||||||||||||||||||||||||||||||||||||||||||
basic | 0.24 | -0.01 | 0.09 | 0.07 | 0.2 | 0.07 | |||||||||||||||||||||||||||||||||||||||
diluted | 0.24 | -0.01 | 0.09 | 0.06 | 0.19 | 0.07 | |||||||||||||||||||||||||||||||||||||||
shares used to compute earnings per common share: | |||||||||||||||||||||||||||||||||||||||||||||
basic | 78,725,139 | 78,391,502 | 78,028,254 | 377,457 | 77,013,831 | 76,538,325 | |||||||||||||||||||||||||||||||||||||||
diluted | 79,691,703 | 78,391,502 | 80,056,024 | 823,320 | 78,464,654 | 77,163,149 | |||||||||||||||||||||||||||||||||||||||
income tax provision | 2,230,000 | 1,627,000 | |||||||||||||||||||||||||||||||||||||||||||
impairment of long-lived assets | 2,754,000 | 185,000 | 429,000 | 32,039,000 | 34,900,000 | ||||||||||||||||||||||||||||||||||||||||
intangible asset amortization | 3,653,000 | 4,563,000 | 5,337,000 | 5,341,000 | 5,329,000 | 5,264,000 | 5,213,000 | 5,391,000 | 5,486,000 | 5,474,000 | 4,983,000 | 3,723,000 | 1,801,000 | 1,273,000 | 1,274,000 | 1,273,000 | 1,275,000 | 601,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | ||||||||||
net income per common share, basic and diluted | -20 | -380 | -410 | -120 | -110 | -50 | -120 | -130 | -200 | -140 | -200 | -130 | -660 | -140 | -80 | -220 | -240 | -160 | -20 | -50 | -50 | -60 | -120 | -180 | -270 | -240 | -210 | -220 | -240 | -120 | -200 | -400 | -360 | -320 | -350 | -340 | -310 | -320 | -6,590 | ||||||
shares used to compute net income per common share, basic and diluted | 74,759,789,000 | 155,886,000 | 72,804,770,000 | 72,478,662,000 | 72,175,457,000 | 93,196,000 | 71,656,694,000 | 71,476,966,000 | 71,229,672,000 | 1,069,674,000 | 69,743,733,000 | 67,316,065,000 | 63,331,702,000 | 1,606,481,000 | 54,858,052,000 | 50,212,123,000 | 49,792,631,000 | 996,675,000 | 48,588,296,000 | 45,586,081,000 | 41,168,593,000 | 1,250,623,000 | 38,620,036,000 | 34,314,234,000 | 34,271,254,000 | 43,912,000 | 33,946,748,000 | 33,873,128,000 | 33,823,889,000 | 965,372,000 | 27,916,819,000 | 27,859,918,000 | 27,817,993,000 | 27,640,806,000 | 26,048,934,000 | 22,539,723,000 | 21,237,196,000 | 21,148,342,000 | 955,890,000 | ||||||
income before income tax benefit | -11,317,000 | -15,479,000 | -9,190,000 | -45,663,000 | |||||||||||||||||||||||||||||||||||||||||
biopharmaceutical revenue | 1,624,000 | 566,000 | 343,000 | 824,000 | 3,779,000 | 722,000 | |||||||||||||||||||||||||||||||||||||||
cost of biopharmaceutical revenue | 560,000 | 81,000 | 49,000 | 204,000 | 252,000 | 116,000 | |||||||||||||||||||||||||||||||||||||||
interest expense | -63,000 | -53,000 | -54,000 | -55,000 | -65,000 | -55,000 | -81,000 | -58,000 | -235,000 | -303,000 | -536,000 | -498,000 | -481,000 | -448,000 | -2,518,000 | -815,000 | -808,000 | -800,000 | -806,000 | -799,000 | -785,000 | ||||||||||||||||||||||||
net income and comprehensive loss | -9,038,000 | -41,868,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | -7,458,000 | -730,000 | -2,494,000 | -1,917,000 | -3,105,000 | -4,469,000 | -6,248,000 | -9,177,000 | -8,439,000 | -7,049,000 | -7,298,000 | -8,217,000 | -4,403,000 | -5,637,000 | -11,243,000 | -10,075,000 | -8,945,000 | -9,136,000 | -7,610,000 | -6,655,000 | -6,674,000 | -6,303,000 | |||||||||||||||||
collaboration revenue | |||||||||||||||||||||||||||||||||||||||||||||
revenue | 22,659,500 | 30,973,000 | 30,136,000 | 29,529,000 | 25,750,000 | 23,466,000 | 22,751,000 | 20,041,000 | 19,596,000 | 17,519,000 | 18,406,000 | 16,432,000 | 18,257,000 | 18,603,000 | 14,675,000 | 13,550,000 | 12,335,000 | 11,908,000 | 11,218,000 | 8,677,000 | 7,476,000 | 5,594,000 | |||||||||||||||||||||||
cost of revenue | 6,601,000 | 9,114,000 | 8,777,000 | 8,513,000 | 8,704,000 | 8,261,000 | 8,246,000 | 7,867,000 | 7,769,000 | 7,169,000 | 6,960,000 | 6,297,000 | 6,515,000 | 6,367,000 | 6,301,000 | 6,279,000 | 5,618,000 | 5,139,000 | 4,566,000 | 3,966,000 | 3,607,000 | 3,132,000 |
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.